We have biomimetic microfluidic chip commercialization systems that reproduces a lung-specific dynamic environment using human-derived primary cells and organoids. Based on this, we have a model system for acute respiratory distress syndrome (ARDS), one of the respiratory diseases, and respiratory infections (viruses, non-tuberculous mycobacteria).